Bruder Healthcare to launch newly branded Eyeleve MGD for dry eye in early 2025
Click Here to Manage Email Alerts
Key takeaways:
- Patients experienced “immediate-onset transient improvement” in tear film stability after 2 weeks.
- Patients reported an improved ability to use the computer at night.
Under a new distribution agreement with Santen SA, Bruder Healthcare will market Eyeleve MGD, the preservative-free ophthalmic emulsion previously sold in the U.S. as Retaine MGD, the company announced in a press release.
The eye drop formulation uses oil-in-water cationic emulsion technology to relieve symptoms of moderate to severe evaporative dry eye, adding moisture by lowering the salt concentration of tears while also lubricating and protecting the surface of the eye.
According to the release, in a study published in Clinical Ophthalmology, the formulation demonstrated therapeutic effect after 2 weeks of treatment, with study participants experiencing “immediate-onset transient improvement” in tear film stability.
The single-center, open-label study included 42 patients (mean age, 61.6 years; 29 women) with dry eye, who were instructed to administer one to two drops twice daily over approximately 2 weeks. Results showed significant reductions in mean breakup area (P = .026), corneal fluorescein staining in all ocular regions (P = .038) and all ocular symptoms (P < .001), as well as patient-reported improvement in working with a computer at night (P = .044).
“This preservative-free drop not only addresses the physiological challenges of dry eye but also enhances patients’ quality of life, particularly in activities like prolonged computer use,” Paul Karpecki, OD, FAAO, co-author of the study, said in the release.
The company plans to market Eyeleve MGD globally in early 2025.
“Adding Eyeleve MGD strengthens our product line and better equips eye care professionals to provide solutions for patients on the road back to healthy eyes,” Brent Jones, Hilco Vision’s global head of vision care solutions, said in the release.
Reference:
- Ousler G, et al. Clin Ophthalmol. 2015;doi:10.2147/OPTH.S75297.
Read more about
Click Here to Manage Email Alerts